Xianxin Hua, MD, PhD University of Pennsylvania
- Status: Active
- Year(s): 2018
- Grant Type: Accelerator
- Research Type: Translational
- Primary Tumor Site: Pancreas
- Area of Inquiry: Immune environment
This 4-year study will develop nanobody-directed CAR T-cell therapy with various combinatory approaches in laboratory models to kill NET cells. The research will be carried out in collaboration with Dr. Carl June at the University of Pennsylvania, whose work was integrally involved with the approval of CAR T-cell therapy, a personalized, breakthrough immunotherapy for blood cancer. The multipronged approaches will significantly increase the opportunity to develop efficacious NET-specific immunotherapy.
- City: Philadelphia
- State: Pennsylvania
- Grant Duration: 4 years
- Sponsor: Margie & Robert E. Petersen Foundation
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.